SCHEMBL6604727

SCHEMBL6604727

C[C@H](N)Cn1ccc2ccc3cccnc3c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 18/20 1.00
HTR2A P28223 17/20 1.00
HTR2B P41595 9/20 1.00
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GMNN O75496 1/20 0.42
TP53 P04637 1/20 0.42
HSP90AA1 P07900 1/20 0.42
MMP2 P08253 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPT P10636 1/20 0.42
MMP9 P14780 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
MMP8 P22894 1/20 0.42
CCR1 P32246 1/20 0.42
THPO P40225 1/20 0.42
MTOR P42345 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6604307 0.81 HTR2C (1.00) HTR2CHTR2AHTR2BCYP3A4
SCHEMBL6603614 0.81 HTR2C (1.00) HTR2CHTR2AHTR2BCYP3A4
SCHEMBL6605040 0.81 HTR2C (1.00) HTR2CHTR2AHTR2BCYP3A4
Hydrochloric Acid SCHEMBL6607981 0.80 HTR2C (0.97) HTR2CHTR2AHTR2BCYP3A4
Hydrochloric Acid SCHEMBL6604400 0.80 HTR2C (0.97) HTR2CHTR2AHTR2BCYP3A4
Ammonia Solution, Strong SCHEMBL6604735 0.79 HTR2A (0.66) HTR2CHTR2AHTR2BLMNAKDM4E
SCHEMBL25818081 0.79 HTR2C (0.65) HTR2CHTR2AHTR2B
SCHEMBL906124 0.77 HTR2A (1.00) HTR2CHTR2AHTR2BCYP3A4CCR1
Phenanthroline SCHEMBL27963166 0.73 CCR1 (0.61) HTR2CHTR2AHTR2BLMNAKDM4E
SCHEMBL7983996 0.73 HTR2C (0.63) HTR2CHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109809-B1 PYRROLOQUINOLINES FOR TREATMENT OF OBESITY CEREBRUS PHARM LTD (GB) 2004-11-17 EP disclosed
US-6365598-B1 FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-02 US disclosed